Article
Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
Clinical lung cancer - 1 Sept 2021
Harada Guilherme, Amano Mariane Tami, Antonacio Fernanda Frozoni, Behar Marina Henkin, Nabuco-de-Araujo Pedro Henrique Xavier, Buchpiguel Carlos Alberto, Junior Gilberto de Castro
Abstract excerpt
Immunotherapy based on immune checkpoint inhibitors (ICIs) either alone or in combination with platinum-based chemotherapy has dramatically changed the therapeutic scenario in non-small cell lung cancer. However, only a subset of patients derives clinical benefits. Although programmed death-ligand 1 (PD-L1) and tumor mutational burden (TMB) are known to be prognostic and demonstrated utility in selecting patients...
Topics
- Adenocarcinoma of Lung
- Antibodies, Monoclonal, Humanized
- DNA-Binding Proteins
- Female
- Humans
- Immunotherapy
- Middle Aged
- Mutation
- Transcription Factors
- Treatment Outcome